CN Patent

CN105853386B — 一种含有达格列净丙二醇水合物的片剂及其制造方法

Assigned to Beijing Chiral-Tech Pharmaceutical Co Ltd · Expires 2020-01-07 · 6y expired

What this patent protects

达格列净是一种新型II型糖尿病治疗药物。本发明涉及一种含有达格列净的片剂的制备工艺，其特征在于首先将达格列净丙二醇水合物溶解在溶剂中制成药物溶液，然后将该药物溶液与稀释剂、粘合剂、崩解剂、润滑剂通过湿法制粒压片，从而得到含有达格列净的片剂。本发明制得的片剂药物含量均匀度好，稳定性好，快速溶出，并且制备工艺简单，易于工业化生产。

USPTO Abstract

达格列净是一种新型II型糖尿病治疗药物。本发明涉及一种含有达格列净的片剂的制备工艺，其特征在于首先将达格列净丙二醇水合物溶解在溶剂中制成药物溶液，然后将该药物溶液与稀释剂、粘合剂、崩解剂、润滑剂通过湿法制粒压片，从而得到含有达格列净的片剂。本发明制得的片剂药物含量均匀度好，稳定性好，快速溶出，并且制备工艺简单，易于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN105853386B
Jurisdiction
CN
Classification
—
Expires
2020-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Chiral-Tech Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.